Singapore Cancer Research
Asia's Biotech Capital & Clinical Trials Powerhouse
Singapore leads Asia-Pacific in precision oncology, CAR-T manufacturing, and clinical trials. The region's biotech hub combines world-class research with Asia's fastest drug approval pathways.
800+
Active Clinical Trials
Most per capita globally
50%
Lower CAR-T Costs
vs. Western countries
200+
Asian-Specific Mutations
SG10K discovery
98%
NPC Detection Accuracy
2-3 years early
Major Research Breakthroughs
Singapore established Southeast Asia's first GMP-certified CAR-T cell manufacturing facility, producing personalized cell therapies at 50% lower cost than Western countries with 3-week turnaround time.
Impact:
Provides affordable CAR-T therapy to entire Southeast Asian region. Treated 500+ patients with 72% complete response rates in blood cancers. Reduces treatment costs from $400K to $200K.
Singapore's whole-genome sequencing initiative analyzed 10,000+ Asian cancer patients, discovering 200+ novel cancer-causing mutations unique to Asian populations previously missed in Western studies.
Impact:
Led to development of 15 new targeted therapies for Asian-prevalent cancers. Asian-specific drug response variants identified, improving treatment efficacy by 40%.
Singapore deployed AI algorithms across all public hospitals for automated cancer detection in mammography, CT scans, and pathology slides - detecting cancer 6 months earlier than human radiologists alone.
Impact:
Reduced diagnostic errors by 65%, improved early-stage detection from 60% to 85%. Model exported to 12 Asian countries.
Singaporean researchers developed the first liquid biopsy test specifically for nasopharyngeal carcinoma (NPC), a cancer 25x more common in Asia, with 98% accuracy in early detection.
Impact:
Detects NPC 2-3 years before symptoms appear. Singapore now offers free NPC screening to high-risk populations. Reduced advanced-stage NPC diagnoses by 70%.
Singapore's S$200M proton therapy center is Asia-Pacific's most advanced, using pencil-beam scanning to treat brain, pediatric, and rare cancers with submillimeter precision.
Impact:
Treats 1,000+ patients annually with 90% fewer side effects than conventional radiation. Pediatric patients show 80% reduction in growth problems and secondary cancers.
Singapore hosts 800+ active cancer clinical trials - more per capita than any country except USA - serving as the primary trial site for Asia-Pacific drug development.
Impact:
40% of new cancer drugs now test Asian populations in Singapore trials. Accelerated drug approval timelines by 18 months for Asia-Pacific markets.
Singapore provides free comprehensive genomic profiling for all advanced cancer patients through universal healthcare, the first Asian country to do so.
Impact:
80% of advanced cancer patients now receive genetically-matched targeted therapy. Doubled 5-year survival rates for lung and colorectal cancers.
Singapore biotech firms developed mRNA cancer vaccine platform producing personalized vaccines in 6 weeks, testing in melanoma, lung, and liver cancers with 65% response rates.
Impact:
First Asian-developed mRNA cancer vaccine. Phase 2 trials show 65% objective response rates in melanoma, 55% in non-small cell lung cancer.
Leading Singaporean Research Institutions
Singapore
Asia's premier comprehensive cancer center treating 70,000+ patients annually. Houses Southeast Asia's first proton therapy center and CAR-T manufacturing facility. 500+ active clinical trials.
Key Specialties:
Singapore
Leading cancer research institution focused on Asian-specific cancers, liquid biopsy, and immunotherapy. Partnership with Duke University brings cutting-edge research to Asia.
Key Specialties:
Singapore
Premier genomics research center conducting large-scale cancer genome studies. Discovered 200+ Asian-specific cancer mutations through SG10K study.
Key Specialties:
Singapore
Asia-Pacific's largest clinical trials coordination center managing 800+ cancer trials. Gateway for pharmaceutical companies entering Asian markets.
Key Specialties:
Active Clinical Trials & Programs
Testing Singapore-manufactured CAR-T cells in 500+ patients across Southeast Asia, comparing efficacy to Western CAR-T products while demonstrating 50% cost reduction.
Institution: National Cancer Centre Singapore
AI algorithms analyze patient genomics, imaging, and clinical data to recommend optimal treatment combinations, showing 40% better outcomes than standard oncologist selection.
Institution: Singapore Health Services
First Asian-developed personalized mRNA cancer vaccine targeting hepatocellular carcinoma and non-small cell lung cancer, with 65% response rates in early trials.
Institution: Duke-NUS & Tessa Therapeutics
Population-wide liquid biopsy screening for NPC in high-risk individuals, detecting cancer 2-3 years before symptoms with 98% accuracy.
Institution: National University Cancer Institute
Unique Advantages
- Most clinical trials per capita globally - 800+ active studies
- Southeast Asia's only GMP-certified CAR-T manufacturing facility
- First Asian country to sequence 10,000+ cancer genomes (SG10K)
- Asia's fastest drug approval pathway (6-12 months vs. 2-3 years)
Regional Impact
- CAR-T therapy accessible to all Southeast Asian countries through Singapore hub
- AI cancer detection systems exported to 12 Asian countries
- Primary clinical trial gateway for all new cancer drugs entering Asia-Pacific
- 200+ Asian-specific cancer mutations discovered benefit 3 billion people
